Key result
HF effusions ≥½ hemithorax predict ~133% greater need for invasive management.
Why the study?
Data on the management and prognosis of heart failure-related pleural effusion in patients undergoing diagnostic thoracentesis are limited, and the significance of invasive pleural interventions remains uncertain.
What are the determinants of pleural drainage and predictors of mortality in patients with heart failure-related pleural effusion?
Cohort (n=1,372)
What are the determinants of pleural drainage and predictors of mortality in patients with heart failure-related pleural effusion?
Hazard Ratio: 2.33
In patients with heart failure-related pleural effusion, mortality is high and driven by systemic markers of advanced heart failure rather than pleural characteristics or the need for invasive pleural interventions.
Neutrophil predominance and elevated NT-proBNP signal higher mortality in HF-related effusions; leaves open whether targeted interventions improve outcomes.
Background Heart failure (HF) is one of the most common causes of pleural effusion (PE), yet data on its management and prognosis in patients undergoing diagnostic thoracentesis are limited. The significance of invasive pleural interventions remains uncertain. Methods We conducted a retrospective analysis of a prospectively maintained pleural database, including consecutive patients with HF-related PE who underwent diagnostic thoracentesis. Clinical characteristics, pleural findings, need for invasive pleural management (therapeutic thoracentesis [TT] or indwelling pleural catheter [IPC]), and mortality were assessed. Fine–Gray competing-risk models and Cox regression were applied. Results A total of 1372 patients were included (median age 85 years). During follow-up, 726 patients (53%) required at least one TT and 81 (6%) received an IPC. In the competing-risk analysis, effusion size ≥½ hemithorax (sHR 2.33), bilateral effusion (sHR 1.37), pleural fluid albumin >1.2 g·dL −1 (sHR 1.23), and male sex (sHR 1.20) were independently associated with invasive pleural management. Median survival was 14 months, with mortality rates of 50% at 1 year and 70% at 2 years. Mortality was independently associated with advanced age, elevated serum NT-proBNP, renal dysfunction, and hypoalbuminemia, whereas pleural characteristics and invasive pleural management were not. Conclusion In patients with HF-related PE undergoing diagnostic thoracentesis, mortality is high and primarily driven by systemic markers of advanced HF. Invasive pleural interventions are frequently required in patients with large or bilateral effusions. In descriptive comparisons, survival was similar regardless of pleural intervention status, although causal inference is precluded by the observational design and time-dependent nature of intervention.
No takes yet. Share an insight, caveat, or question.
Porcel et al. (2026) conducted a cohort in Heart failure-related pleural effusion (n=1,372). Effusion size ≥½ hemithorax vs. Smaller effusion size was evaluated on Invasive pleural management (sHR 2.33). In patients with HF-related pleural effusion, effusion size ≥½ hemithorax predicted invasive management (sHR 2.33), while mortality (50% at 1 year) was driven by systemic markers of advanced HF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: